相关临床试验
69
37 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
1.4%
已完成
22
31.9%
尚未招募
36
52.2%
招募中
9
13.0%
暂停
1
1.4%
暂无批准数据
- The Indian Pharmacopoeia Commission (IPC) will spearhead a National Sensitization and Capacity Building Programme on Materiovigilance on July 10, 2026, at NIMHANS Bengaluru. - The initiative aims to strengthen competencies in medical device adverse event reporting, with a focus on AI/ML integration for signal detection and proactive surveillance. - The programme brings together healthcare professionals, regulators, biomedical engineers, and industry stakeholders under the theme "Safeguarding Patients through Robust Medical Device Safety and Vigilance Systems." - Participants will gain hands-on exposure to the ADRMS digital reporting portal and real-world safety case studies, with registration open until June 30, 2026.
- Researchers at TIFR have identified a specific neuron in the ventral hippocampus that, when activated, can alleviate anxiety in rodents. - The study used the synthetic psychedelic drug DOI to target and trace the PV-positive neuron responsible for reducing anxiety without hallucinations. - This discovery could lead to more targeted treatments and the development of psychedelic-inspired medications for treatment-resistant mental health conditions. - The research team collaborated with multiple institutions, including Cornell, Yale, and Columbia universities, to validate their findings.
